SCHEMBL4191067

SCHEMBL4191067

O=C(O)c1ccc(-c2ncc(Cl)cc2Cl)cc1F

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 2/20 0.47
TSHR P16473 1/20 0.44
CASP1 P29466 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RARB P10826 4/20 0.43
RARA P10276 3/20 0.43
RARG P13631 2/20 0.43
AXL P30530 1/20 0.42
SCN9A Q15858 1/20 0.42
RORC P51449 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
KMO O15229 5/20 0.41
SLC22A12 Q96S37 2/20 0.40
XDH P47989 1/20 0.40
CNR2 P34972 1/20 0.40
RPA1 P27694 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4184573 0.87 TSHR (0.56) DHODHTSHRCASP1SMN1; SMN2KMO
SCHEMBL4179360 0.84 SORT1 (0.51) SMN1; SMN2RORCMRGPRX4
SCHEMBL4182257 0.80 KDM4E (0.47) DHODHSMN1; SMN2RARBRARARARG
SCHEMBL4186527 0.77 ADH5 (0.58) TSHRSMN1; SMN2MRGPRX4CNR2
SCHEMBL16608990 0.77 RPA1 (0.58) DHODHTSHRCASP1SMN1; SMN2RARB
SCHEMBL31227325 0.77 LMNA (0.44) SMN1; SMN2RARBRARARARGAXL
SCHEMBL22924894 0.77 CYP11B1 (0.55) RARBRARARARGSLC22A12XDH
SCHEMBL6017915 0.75 RARB (0.55) DHODHTSHRCASP1SMN1; SMN2RARB
SCHEMBL5111947 0.75 ALDH1A1 (0.56) DHODHSMN1; SMN2MRGPRX4KMOXDH
SCHEMBL24852574 0.74 PDK1 (0.48) RARBRARARARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9199965-B2 Benzoimidazole derivatives and pharmaceutical composition comprising the same DAEWOONG CO., LTD. (KR) 2015-12-01 US disclosed
EP-1861387-B1 BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF DAE WOONG PHARMA (KR) 2014-04-16 EP disclosed
CN-101128452-B Novel benzimidazole derivatives and pharmaceutical compositions containing the same DAE WOONG PHARMA 2012-11-21 CN disclosed
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2009-01-15 US disclosed
CN-101128452-A Novel benzimidazole derivatives and pharmaceutical compositions containing the same DAE WOONG PHARMA (KR) 2008-02-20 CN disclosed
EP-1861387-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2007-12-05 EP disclosed
WO-2006080821-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018124-A1 Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same TRPV1, TRPA1, BDKRB2 DHODH 1246/4885TSHR 2576/4885CASP1 848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.